BACKGROUND Cellulose acetate phthalate (CAP) in soluble form blocks coreceptor binding sites on the virus envelope glycoprotein gp120 and elicits gp41 six-helix bundle formation, processes involved in virus inactivation. CAP is not soluble at pH < 5.5, normal for microbicide target sites. Therefore, the interaction between insoluble micronized CAP and HIV-1 was studied. Carbomer 974P/BufferGel;...

  Objective(s): The aim of the present study is to determine the effect of Chloramphenicol (CAP) on rat liver and small intestine. Effect of phenobarbital (PB) on CAP toxicity was also investigated.   Materials and Methods:   Rats were received CAP at doses of 0, 200, 400 and 600 mg/kg. Another group was pretreated with 80 mg/kg PB 30 min prior to administration of various doses...

Background and purpose: Cancer is one of the major health challenges in the world. The efficacy of current treatments is low but their side effects are high. Cold atmospheric plasma (CAP) is a new modality for cancer treatment. This study aimed to compare the cytotoxicity effect of CAP on the cell line models of common cancers and normal cells. Materials and methods: In this experimental study...

Monocyte chemoattractant protein (MCP)-1 increases in the serum of immunocompetent patients with community-acquired pneumonia (CAP). However, the correlation between the circulating level of MCP-1 and severity of CAP remains unclear. This study investigated differential changes in the plasma MCP-1 levels of patients with CAP before and after an antibiotic treatment and further analyzes the asso...

BACKGROUND Recent evidence demonstrates increased short-term risk of cardiac complications and respiratory failure among patients with heart failure (HF) and chronic obstructive pulmonary disease (COPD), respectively, concurrent with an episode of community-acquired pneumonia (CAP). We evaluated patients with pre-existing HF or COPD, beginning 30 days after CAP diagnosis, to determine if CAP ha...

twenty-one patients with advanced breast cancer (7 premenopausal and 14 postmenopausal women) were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin (cap). the median age of the patients was 43 years (range 36-61). this therapy was repeated every 3 weeks. nine patients (group 1) received cap as primary therapy for metastatic breast cancer, and twelve patients (group 2) ...